US 12,390,506 B2
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
James D. Pipkin, Lawrence, KS (US); Roger A. Rajewski, Lawrence, KS (US); and Beau Mainous, Duluth, GA (US)
Assigned to CyDex Pharmaceuticals, Inc., San Diego, CA (US); and University of Kansas, Lawrence, KS (US)
Filed by CyDex Pharmaceuticals, Inc., Emeryville, CA (US); and University of Kansas, Lawrence, KS (US)
Filed on Jun. 29, 2022, as Appl. No. 17/853,761.
Application 17/853,761 is a division of application No. 16/920,127, filed on Jul. 2, 2020, granted, now 11,382,944.
Application 16/920,127 is a division of application No. 15/559,005, granted, now 10,702,568, issued on Jul. 7, 2020, previously published as PCT/US2016/023309, filed on Mar. 18, 2016.
Claims priority of provisional application 62/135,625, filed on Mar. 19, 2015.
Prior Publication US 2023/0233638 A1, Jul. 27, 2023
Int. Cl. A61K 36/28 (2006.01); A61K 8/49 (2006.01); A61K 8/73 (2006.01); A61K 8/96 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/353 (2006.01); A61K 31/357 (2006.01); A61K 47/40 (2006.01); A61P 1/16 (2006.01); A61P 17/06 (2006.01); A61Q 17/04 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 36/28 (2013.01) [A61K 8/498 (2013.01); A61K 8/738 (2013.01); A61K 8/96 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/353 (2013.01); A61K 31/357 (2013.01); A61K 47/40 (2013.01); A61P 1/16 (2018.01); A61P 17/06 (2018.01); A61Q 19/08 (2013.01); A61K 2300/00 (2013.01); A61Q 17/04 (2013.01)] 26 Claims
 
1. A pill, capsule, tablet or emulsion comprising:
taxifolin, silychristin, silydianin, silybin A, silybin B, isosilybin A, isosilybin B, and
sulfoalkyl ether cyclodextrin,
wherein the molar ratio of taxifolin to sulfoalkyl ether cyclodextrin is in the range of about 0.02 to 0.25, wherein the molar ratio of silycristin to sulfoalkyl ether cyclodextrin is in the range of about 0.06 to 0.25, wherein the molar ratio of silydianin to sulfoalkyl ether cyclodextrin is in the range of about 0.08 to 0.25, wherein the molar ratio of silybin A to sulfoalkyl ether cyclodextrin is in the range of about 0.01 to 0.07, wherein the molar ratio of silybin B to sulfoalkyl ether cyclodextrin is in the range of about 0.04 to 0.15, wherein the molar ratio of isosilybin A to sulfoalkyl ether cyclodextrin is in the range of about 0.02 to 0.09, and wherein the molar ratio of isosilybin B to sulfoalkyl ether cyclodextrin is in the range of about 0.002 to 0.03.